• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞毒性T淋巴细胞相关抗原4(CTLA-4)介导的抑制性信号在外周T细胞耐受中起作用?

A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?

作者信息

Allison J P, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M

机构信息

Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley 94720-3200, USA.

出版信息

Novartis Found Symp. 1998;215:92-8; discussion 98-102, 186-90. doi: 10.1002/9780470515525.ch7.

DOI:10.1002/9780470515525.ch7
PMID:9760573
Abstract

Occupancy of the antigen receptor is not sufficient for activation of naïve T cells--additional co-stimulatory signals are required that can be provided only by 'professional' antigen-presenting cells. This two-signal model for T cell activation has been thought to provide a mechanism for the induction and maintenance of peripheral tolerance. Work over the past six years has demonstrated that the relevant co-stimulatory receptor on T cells is the molecule CD28. Recent data shows that the CD28 homologue CTLA-4 plays a role in negative regulation of T cell responses. Here we suggest that CTLA-4 may also serve as an attenuator of T cell-activating signals, raising the threshold of stimulation required to obtain full activation. The inhibitory signals mediated by CTLA-4 may provide an additional mechanism for the maintenance of peripheral tolerance.

摘要

抗原受体的占据不足以激活初始T细胞——还需要额外的共刺激信号,而这些信号只能由“专职”抗原呈递细胞提供。T细胞激活的这种双信号模型被认为提供了一种诱导和维持外周耐受的机制。过去六年的研究表明,T细胞上相关的共刺激受体是分子CD28。最近的数据显示,CD28同源物CTLA-4在T细胞反应的负调节中发挥作用。在此我们提出,CTLA-4也可能作为T细胞激活信号的衰减器,提高获得完全激活所需的刺激阈值。由CTLA-4介导的抑制性信号可能为维持外周耐受提供一种额外机制。

相似文献

1
A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?细胞毒性T淋巴细胞相关抗原4(CTLA-4)介导的抑制性信号在外周T细胞耐受中起作用?
Novartis Found Symp. 1998;215:92-8; discussion 98-102, 186-90. doi: 10.1002/9780470515525.ch7.
2
The role of CTLA-4 in the regulation and initiation of T-cell responses.CTLA-4在T细胞反应的调节与启动中的作用。
Immunol Rev. 1996 Oct;153:27-46. doi: 10.1111/j.1600-065x.1996.tb00919.x.
3
CTLA-4 and T cell activation.细胞毒性T淋巴细胞相关抗原4与T细胞活化
Curr Opin Immunol. 1999 Jun;11(3):294-300. doi: 10.1016/s0952-7915(99)80047-8.
4
Co-stimulation in T cell responses.T细胞应答中的共刺激
Curr Opin Immunol. 1997 Jun;9(3):396-404. doi: 10.1016/s0952-7915(97)80087-8.
5
The complexities of T-cell co-stimulation: CD28 and beyond.T细胞共刺激的复杂性:CD28及其他
Immunol Rev. 1996 Oct;153:155-82. doi: 10.1111/j.1600-065x.1996.tb00924.x.
6
The role of CTLA-4 in the regulation of T cell immune responses.
Immunol Cell Biol. 1999 Feb;77(1):1-10. doi: 10.1046/j.1440-1711.1999.00795.x.
7
The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.B7-1/B7-2:CD28/CLTA-4通路在预防无反应性、诱导有效免疫及下调免疫反应中的作用。
Immunol Rev. 1996 Oct;153:5-26. doi: 10.1111/j.1600-065x.1996.tb00918.x.
8
T-cell regulation by CD28 and CTLA-4.CD28和CTLA-4对T细胞的调节
Nat Rev Immunol. 2001 Dec;1(3):220-8. doi: 10.1038/35105024.
9
CTLA-4 is required for the induction of high dose oral tolerance.诱导高剂量口服耐受需要CTLA-4。
Int Immunol. 1998 Apr;10(4):491-8. doi: 10.1093/intimm/10.4.491.
10
Antigen presentation by parenchymal cells: a route to peripheral tolerance?实质细胞的抗原呈递:通向外周耐受的途径?
Immunol Rev. 1999 Dec;172:297-314. doi: 10.1111/j.1600-065x.1999.tb01374.x.

引用本文的文献

1
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).黑色素瘤的抗体疗法:激活免疫的新机遇与新兴机会(综述)
Oncol Rep. 2014 Sep;32(3):875-86. doi: 10.3892/or.2014.3275. Epub 2014 Jun 20.
2
Therapeutic cancer vaccines.治疗性癌症疫苗
Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0.
3
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.依匹木单抗联合前列腺特异性抗原靶向的痘病毒疫苗治疗转移性去势抵抗性前列腺癌:一项 I 期剂量爬坡试验。
Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.
4
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.Sipuleucel-T:前列腺癌治疗新时代的先兆。
Expert Rev Vaccines. 2011 Feb;10(2):141-50. doi: 10.1586/erv.10.173.
5
Therapeutic cancer vaccines: the latest advancement in targeted therapy.治疗性癌症疫苗:靶向治疗的最新进展。
Am J Ther. 2012 Nov;19(6):e172-81. doi: 10.1097/MJT.0b013e3182068cdb.
6
The current and emerging role of immunotherapy in prostate cancer.免疫疗法在前列腺癌中的现状和新进展。
Clin Genitourin Cancer. 2010 Dec 1;8(1):10-6. doi: 10.3816/CGC.2010.n.002.
7
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.前列腺癌的治疗性癌症疫苗:生存时间改善而无进展时间变化的悖论。
Oncologist. 2010;15(9):969-75. doi: 10.1634/theoncologist.2010-0129. Epub 2010 Aug 26.
8
Combining Vaccines with Conventional Therapies for Cancer.将疫苗与癌症传统疗法相结合。
Update Cancer Ther. 2007 Mar;2(1):33-39. doi: 10.1016/j.uct.2007.04.004.
9
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.通过与其他方式联合使用来提高治疗性疫苗的疗效。
Vaccine. 2007 Sep 27;25 Suppl 2(Suppl 2):B89-96. doi: 10.1016/j.vaccine.2007.04.091. Epub 2007 Jun 4.
10
Immunotherapy for advanced prostate cancer.晚期前列腺癌的免疫疗法。
Rev Urol. 2007;9 Suppl 1(Suppl 1):S29-38.